
FDA Review of Compounded Peptides Draws Attention as Regulatory Debate Intensifies
FDA compounded peptides are once again at the center of a national discussion. Regulators, healthcare professionals and pharmacy organizations are evaluating how certain experimental peptide ingredients should be handled under existing U.S. regulations. The outcome of the current review could influence how patients, physicians and licensed compounding pharmacies access these substances











